Feature|Articles|September 17, 2024
- Pharmaceutical Executive: September 2024
- Volume 44
- Issue 9
Pharmaceutical Executive: September 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive September 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 1 year ago
A Care Sea Changeover 1 year ago
Jan van de Winkel: Antibody Ascensionover 1 year ago
Biotech Performance Pivot May Be in the Offingover 1 year ago
Delivery and Disruption: Navigating a Changing Care Terrainover 1 year ago
Outsourcing’s Evolution in the Pharma Industryover 1 year ago
A Risk-Reward Reset: Getting Serious About Social Mediaover 1 year ago
Copay Adjustment Chess Match: What Will Payers Do Next?over 1 year ago
Rx Power Struggle: How Pharma can Flip the PBM ScriptAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Makes Leadership Overhaul Following Commissioner Makary’s Departure: Report
2
The Risks and Benefits of FDA Reviewing Real-Time Data
3
Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates
4
FDA Approves Baxdrostat for Uncontrolled Hypertension in First-in-Class Entry
5